Published in Malar J on November 03, 2014
Pharmacokinetic, Pharmacogenetic, and Other Factors Influencing CNS Penetration of Antiretrovirals. AIDS Res Treat (2016) 0.75
Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet (2001) 5.80
Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther (1994) 5.22
Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. Am J Epidemiol (2009) 4.70
Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther (2013) 3.81
Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev (2002) 3.73
Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol (1998) 3.17
The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician (2007) 2.74
High prevalence of the CYP2B6 516G-->T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. Eur J Clin Pharmacol (2007) 2.68
In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol (1998) 2.45
Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol (2001) 2.38
Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev (2009) 2.16
Cytochrome P450s and other enzymes in drug metabolism and toxicity. AAPS J (2006) 2.13
Structure of human microsomal cytochrome P450 2C8. Evidence for a peripheral fatty acid binding site. J Biol Chem (2003) 2.09
CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme. Curr Drug Metab (2008) 2.06
Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenet Genomics (2005) 1.95
Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance. Pharmacogenomics (2007) 1.84
Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol Sci (1999) 1.77
Clinical impact of patient population differences and genomic variation in efavirenz therapy. AIDS (2008) 1.71
Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance. Clin Pharmacol Ther (2005) 1.51
Increased transcriptional activity of the CYP3A4*1B promoter variant. Environ Mol Mutagen (2003) 1.42
Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: implications for malaria treatment in Africa. Clin Pharmacol Ther (2007) 1.39
Safety and tolerability of combination antimalarial therapies for uncomplicated falciparum malaria in Ugandan children. Malar J (2008) 1.27
CYP3A5 genetic polymorphisms in different ethnic populations. Drug Metab Dispos (2005) 1.19
Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population. BMC Med Genet (2009) 1.17
Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations. PLoS One (2013) 1.17
Gene structure of CYP3A4, an adult-specific form of cytochrome P450 in human livers, and its transcriptional control. Eur J Biochem (1993) 1.17
Pharmacogenetics of antimalarial drugs: effect on metabolism and transport. Lancet Infect Dis (2009) 1.16
Ethnic differences in the frequency of prostate cancer susceptibility alleles at SRD5A2 and CYP3A4. Hum Hered (2002) 1.16
Frequencies of Cytochrome P450 2B6 and 2C8 Allelic Variants in the Mozambican Population. Malays J Med Sci (2013) 1.16
Phenotype-genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles. Biochem Biophys Res Commun (2005) 1.15
Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies. Pharmacogenomics (2009) 1.15
Estimation of drug-metabolizing capacity by cytochrome P450 genotyping and expression. J Pharmacol Exp Ther (2012) 1.15
Determinants of cytochrome P450 2C8 substrate binding: structures of complexes with montelukast, troglitazone, felodipine, and 9-cis-retinoic acid. J Biol Chem (2008) 1.14
Effect of concomitant artesunate administration and cytochrome P4502C8 polymorphisms on the pharmacokinetics of amodiaquine in Ghanaian children with uncomplicated malaria. Antimicrob Agents Chemother (2008) 1.10
CYP2C8 polymorphism frequencies among malaria patients in Zanzibar. Eur J Clin Pharmacol (2005) 1.08
Population pharmacokinetics of chloroquine and sulfadoxine and treatment response in children with malaria: suggestions for an improved dose regimen. Br J Clin Pharmacol (2008) 1.04
Genetic variants in CYP (-1A2, -2C9, -2C19, -3A4 and -3A5), VKORC1 and ABCB1 genes in a black South African population: a window into diversity. Pharmacogenomics (2011) 1.01
Organization, structure and evolution of the CYP2 gene cluster on human chromosome 19. Pharmacogenetics (2001) 1.01
Short communication: high prevalence of the cytochrome P450 2C8*2 mutation in Northern Ghana. Trop Med Int Health (2005) 0.98
The human CYP2C locus: a prototype for intergenic and exon repetition splicing events. Genomics (2000) 0.96
Effect of single nucleotide polymorphisms in cytochrome P450 isoenzyme and N-acetyltransferase 2 genes on the metabolism of artemisinin-based combination therapies in malaria patients from Cambodia and Tanzania. Antimicrob Agents Chemother (2012) 0.95
African variation at Cytochrome P450 genes: Evolutionary aspects and the implications for the treatment of infectious diseases. Evol Med Public Health (2013) 0.95
Human liver expression of CYP2C8: gender, age, and genotype effects. Drug Metab Dispos (2010) 0.95
Molecular diversity and population structure at the Cytochrome P450 3A5 gene in Africa. BMC Genet (2013) 0.94
Pharmacogenetics in drug regulation: promise, potential and pitfalls. Philos Trans R Soc Lond B Biol Sci (2005) 0.93
Molecular mechanisms of resistance in antimalarial chemotherapy: the unmet challenge. Annu Rev Pharmacol Toxicol (2005) 0.93
Polymorphism of antimalaria drug metabolizing, nuclear receptor, and drug transport genes among malaria patients in Zanzibar, East Africa. Ther Drug Monit (2008) 0.93
The pharmacogenetics of antimalaria artemisinin combination therapy. Expert Opin Drug Metab Toxicol (2011) 0.87
CYP3A4*1B and NAT2*14 alleles in a native African population. Clin Chem Lab Med (2003) 0.86
CYP3A4 promoter variant in Saudi, Ghanaian and Scottish Caucasian populations. Pharmacogenetics (2000) 0.86
Cytochrome P450 pharmacogenetics in African populations. Drug Metab Rev (2013) 0.85
A pharmacogenetic study of CD4 recovery in response to HIV antiretroviral therapy in two South African population groups. J Hum Genet (2009) 0.84
Pharmacogenetics of cytochrome P450 (CYP) in the elderly. Ageing Res Rev (2010) 0.84
Genetic polymorphisms in MDR1, CYP3A4 and CYP3A5 genes in a Ghanaian population: a plausible explanation for altered metabolism of ivermectin in humans? BMC Med Genet (2010) 0.83
Influence of CYP2B6 and ABCB1 SNPs on nevirapine plasma concentrations in Burundese HIV-positive patients using dried sample spot devices. Br J Clin Pharmacol (2012) 0.83
Characterization of the genetic variation present in CYP3A4 in three South African populations. Front Genet (2013) 0.82
Distribution of human CYP2C8*2 allele in three different African populations. Malar J (2012) 0.81
A microarray-based system for the simultaneous analysis of single nucleotide polymorphisms in human genes involved in the metabolism of anti-malarial drugs. Malar J (2009) 0.78
Patterns of pharmacogenetic diversity in African populations: role of ancient and recent history. Pharmacogenomics (2009) 0.77
Absence of the human CYP2C8*3 allele in Ugandan children exposed to Plasmodium falciparum malaria. Infect Genet Evol (2014) 0.76
Predictors of positive blood culture and deaths among neonates with suspected neonatal sepsis in a tertiary hospital, Mwanza-Tanzania. BMC Pediatr (2010) 2.06
Detection of a substantial number of sub-microscopic Plasmodium falciparum infections by polymerase chain reaction: a potential threat to malaria control and diagnosis in Ethiopia. Malar J (2013) 1.56
Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine. Am J Trop Med Hyg (2014) 1.51
Prevalence of multiresistant gram-negative organisms in a tertiary hospital in Mwanza, Tanzania. BMC Res Notes (2009) 1.49
Adoption of the new antimalarial drug policy in Tanzania--a cross-sectional study in the community. Trop Med Int Health (2005) 1.39
Evidence of Plasmodium falciparum malaria resistant to atovaquone and proguanil hydrochloride: case reports. BMJ (2003) 1.31
Impaired fitness of drug-resistant malaria parasites: evidence and implication on drug-deployment policies. Expert Rev Anti Infect Ther (2009) 1.18
Genotyping of methicillin-resistant Staphylococcus aureus strains from two hospitals in Bangalore, South India. J Clin Microbiol (2005) 1.12
Polyclonal Plasmodium falciparum malaria in travelers and selection of antifolate mutations after proguanil prophylaxis. Am J Trop Med Hyg (2002) 1.06
Efficacy of artemether-lumefantrine in treatment of malaria among under-fives and prevalence of drug resistance markers in Igombe-Mwanza, north-western Tanzania. Malar J (2012) 1.05
Locomotor deficiencies and aberrant development of subtype-specific GABAergic interneurons caused by an unliganded thyroid hormone receptor alpha1. J Neurosci (2008) 1.00
Skin cancers among Albinos at a University teaching hospital in Northwestern Tanzania: a retrospective review of 64 cases. BMC Dermatol (2012) 0.98
Cotrimoxazole resistance of Streptococcus pneumoniae and commensal streptococci from Kampala, Uganda. Scand J Infect Dis (2009) 0.94
Risk factors for mortality among HIV-positive patients with and without active tuberculosis in Dar es Salaam, Tanzania. Antivir Ther (2011) 0.94
Predominance of methicillin resistant Staphylococcus aureus -ST88 and new ST1797 causing wound infection and abscesses. J Infect Dev Ctries (2012) 0.94
Large differences in prevalence of Pfcrt and Pfmdr1 mutations between Mwanza, Tanzania and Iganga, Uganda-a reflection of differences in policies regarding withdrawal of chloroquine? Acta Trop (2011) 0.92
Clarithromycin treatment selects for persistent macrolide-resistant bacteria in throat commensal flora. Int J Antimicrob Agents (2005) 0.91
Plasmodium falciparum: higher incidence of molecular resistance markers for sulphadoxine than for pyrimethamine in Kasangati, Uganda. Trop Med Int Health (2005) 0.90
Distinct haplotypes of dhfr and dhps among Plasmodium falciparum isolates in an area of high level of sulfadoxine-pyrimethamine (SP) resistance in eastern Sudan. Infect Genet Evol (2009) 0.89
Prevalence and factors associated with Group A rotavirus infection among children with acute diarrhea in Mwanza, Tanzania. J Infect Dev Ctries (2012) 0.86
Adherence to antiretroviral therapy among HIV infected children measured by caretaker report, medication return, and drug level in Dar Es Salaam, Tanzania. BMC Pediatr (2013) 0.86
Mutations and horizontal transmission have contributed to sulfonamide resistance in Streptococcus pyogenes. Microb Drug Resist (2003) 0.85
Sulphonamide resistant commensal Neisseria with alterations in the dihydropteroate synthase can be isolated from carriers not exposed to sulphonamides. BMC Microbiol (2002) 0.83
Novel function assignment to a member of the essential HP1043 response regulator family of epsilon-proteobacteria. Microbiology (2013) 0.80
Comparison of bioavailability between the most available generic tablet formulation containing artemether and lumefantrine on the Tanzanian market and the innovator's product. Malar J (2013) 0.80
Transmission and cross-mating of high-level resistance Plasmodium falciparum dihydrofolate reductase haplotypes in The Gambia. Am J Trop Med Hyg (2010) 0.80
Cotrimoxazole Prophylaxis Specifically Selects for Cotrimoxazole Resistance in Streptococcus mutans and Streptococcus sobrinus with Varied Polymorphisms in the Target Genes folA and folP. Int J Microbiol (2012) 0.80
Relationship between non-Hodgkin's lymphoma and blood levels of Epstein-Barr virus in children in north-western Tanzania: a case control study. BMC Pediatr (2013) 0.80
Hydroxymethyldihydropterin pyrophosphokinase from Plasmodium falciparum complements a folK-knockout mutant in E. coli when expressed as a separate polypeptide detached from dihydropteroate synthase. Mol Biochem Parasitol (2005) 0.80
Enlarged lateral ventricles and aberrant behavior in mice overexpressing PDGF-B in embryonic neural stem cells. Exp Cell Res (2010) 0.79
Probing the roles of non-homologous insertions in the N-terminal domain of Plasmodium falciparum hydroxymethylpterin pyrophosphokinase-dihydropteroate synthase. Mol Biochem Parasitol (2009) 0.79
Impaired Ca2+ handling and contraction in cardiomyocytes from mice with a dominant negative thyroid hormone receptor alpha1. J Mol Cell Cardiol (2005) 0.78
High prevalence of pfcrt-CVIET haplotype in isolates from asymptomatic and symptomatic patients in south-central Oromia, Ethiopia. Malar J (2014) 0.78
Macrolide resistance can be transferred by conjugation from viridans streptococci to Streptococcus pyogenes. Int J Antimicrob Agents (2006) 0.77
Albinism and disease causing pathogens in Tanzania: are alleles that are associated with OCA2 being maintained by balancing selection? Med Hypotheses (2012) 0.77
High prevalence of Plasmodium falciparum pfcrt K76T mutation in children with sickle cell disease at a tertiary hospital in north-western Tanzania. Tanzan J Health Res (2014) 0.75
Predictors of outcome among patients with obstructive jaundice at Bugando Medical Centre in north-western Tanzania. Tanzan J Health Res (2013) 0.75